<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Edesa Biotech Inc — News on 6ix</title>
<link>https://6ix.com/company/edesa-biotech-inc</link>
<description>Latest news and press releases for Edesa Biotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 20:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/edesa-biotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835617e78dffbe2df0ee716.webp</url>
<title>Edesa Biotech Inc</title>
<link>https://6ix.com/company/edesa-biotech-inc</link>
</image>
<item>
<title>Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-invited-for-oral-showcase-at-respiratory-innovation-summit</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-invited-for-oral-showcase-at-respiratory-innovation-summit</guid>
<pubDate>Tue, 31 Mar 2026 20:20:00 GMT</pubDate>
<description>Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS PatientsTORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that its chief executive officer, Dr. Par Nijhawan, has been selected to deliver the inaugural presentation at the Oral Showcase at the ATS 2</description>
</item>
<item>
<title>Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-advances-vitiligo-program-for-planned-mid-2026-enrollment</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-advances-vitiligo-program-for-planned-mid-2026-enrollment</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed</description>
</item>
<item>
<title>Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-additional-positive-results-from-phase-3-paridiprubart-study</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-additional-positive-results-from-phase-3-paridiprubart-study</guid>
<pubDate>Tue, 24 Feb 2026 14:15:00 GMT</pubDate>
<description>Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional patent applications for sepsis, acute kidney injury and pneumoniaStrategic collaborations to support late-stage development and commercialization being evaluatedStudy results selected for oral presentation at ATS 2026 conference TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasda</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal 1st Quarter 2026 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-1st-212000006</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-1st-212000006</guid>
<pubDate>Fri, 13 Feb 2026 21:20:00 GMT</pubDate>
<description>TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study i</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal Year 2025 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2025-212000926</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2025-212000926</guid>
<pubDate>Fri, 12 Dec 2025 21:20:00 GMT</pubDate>
<description>TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients</description>
</item>
<item>
<title>Edesa Biotech Announces Upcoming Conference Schedule</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-upcoming-conference-203000250</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-upcoming-conference-203000250</guid>
<pubDate>Fri, 31 Oct 2025 20:30:00 GMT</pubDate>
<description>TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Vienna, Austria, November 3-5, 2025LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT. To schedule a meeting with Ed</description>
</item>
<item>
<title>Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-positive-results-114500682</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-positive-results-114500682</guid>
<pubDate>Tue, 28 Oct 2025 11:45:00 GMT</pubDate>
<description>Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announce</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-3rd-203500823</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-3rd-203500823</guid>
<pubDate>Fri, 08 Aug 2025 20:35:00 GMT</pubDate>
<description>TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business. During the quarter, the company advanced manufacturing-related activities to support U.S. regulatory approval of a Phase 2 study of Edesa’s drug candidate EB06 (an anti-CXCL</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2nd-201500493</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2nd-201500493</guid>
<pubDate>Wed, 14 May 2025 20:15:00 GMT</pubDate>
<description>TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2025 and provided an update on its business. During the quarter, the company completed a $15 million equity financing from healthcare-focused institutional investors, existing Edesa shareholders and insiders to support</description>
</item>
<item>
<title>Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-participate-bloom-burton-203000796</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-participate-bloom-burton-203000796</guid>
<pubDate>Mon, 28 Apr 2025 20:30:00 GMT</pubDate>
<description>TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the co</description>
</item>
<item>
<title>Edesa Biotech Announces Chief Financial Officer Transition</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-chief-financial-201500670</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-chief-financial-201500670</guid>
<pubDate>Fri, 04 Apr 2025 20:15:00 GMT</pubDate>
<description>TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in fin</description>
</item>
<item>
<title>Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-dollar150-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-dollar150-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Thu, 13 Feb 2025 05:00:00 GMT</pubDate>
<description>Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s</description>
</item>
<item>
<title>BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/barda-selects-edesa-biotechs-drug-for-us-funded-platform-trial-in-general-ards</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/barda-selects-edesa-biotechs-drug-for-us-funded-platform-trial-in-general-ards</guid>
<pubDate>Mon, 24 Jun 2024 04:00:00 GMT</pubDate>
<description>This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2nd-quarter-2024-results</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-2nd-quarter-2024-results</guid>
<pubDate>Fri, 10 May 2024 04:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal 1st Quarter 2024 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-1st-quarter-2024-results</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-1st-quarter-2024-results</guid>
<pubDate>Fri, 09 Feb 2024 05:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal Year 2023 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-year-2023-results</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-year-2023-results</guid>
<pubDate>Fri, 15 Dec 2023 05:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Edesa Biotech Secures $10 Million Credit Facility with Company Founder </title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-secures-dollar10-million-credit-facility-with-company-founder</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-secures-dollar10-million-credit-facility-with-company-founder</guid>
<pubDate>Thu, 12 Oct 2023 04:00:00 GMT</pubDate>
<description>Revolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA)</description>
</item>
<item>
<title>Edesa Biotech Announces One-for-Seven Reverse Share Split</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-one-for-seven-reverse-share-split</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-announces-one-for-seven-reverse-share-split</guid>
<pubDate>Tue, 10 Oct 2023 04:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused</description>
</item>
<item>
<title>Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-publishes-phase-2-substudy-results-of-ards-drug-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-publishes-phase-2-substudy-results-of-ards-drug-candidate</guid>
<pubDate>Thu, 28 Sep 2023 04:00:00 GMT</pubDate>
<description>Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with</description>
</item>
<item>
<title>Edesa Biotech Reports Fiscal Third Quarter 2023 Results</title>
<link>https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-third-quarter-2023-results</link>
<guid isPermaLink="true">https://6ix.com/company/edesa-biotech-inc/news/edesa-biotech-reports-fiscal-third-quarter-2023-results</guid>
<pubDate>Wed, 09 Aug 2023 04:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and</description>
</item>
</channel>
</rss>